Great Corporate Overview Update! Very professionally done and every time I think I know all of IPIX’s near term opportunities, I learn something new. See the paragraph below. Leo could announce CV19 Grant funding, initiation of FDA CV19 human trials, peer review publications and/or BP partnerships at any time. Leo could also completely surprise us like he did with the European Subsidiary news that NO ONE saw coming. Brilacidin keeps moving closer to market approval on multiple fronts as a franchise drug. IMO 2020 is going to be a very profitable year for IPIX shareholders.
=====================================================
From page 11
Brilacidin may be well-suited for nebulized delivery See: “Inhaler with Electrostatic Sterilizer and Use of Cationic Amphiphilic Peptides May Accelerate Recovery from COVID-19.” Biotechniques. 2020 Jun 17.